Cannabinoid Research Agreement sets out to find the Cure for Cancer
CURE Pharmaceutical has announced that in collaboration with other leading pharmaceutical and cancer technologies organizations to find substantial evidence in different cannabinoid compounds to treat various subtypes of cancer in children. The partners joining CURE Pharmaceuticals include CannaKids and Technion Israel Institute of Technology.
The organizations are hopeful that with this research, cancer patients will potentially find a more perfect match for their specific ailments with the medical cannabis strains that can best help their symptoms and situations. Several previous clinical studies have demonstrated the efficiency of using of cannabinoids to regress or stop different cancers.
Technion is one of the leading cannabis laboratories in the word and with this partnership, the Technion team aims to clarify the antitumor effects of phytocannabinoids and terpenes on various cancer-driving mutations and pathways, as well as further revealing the mechanisms of the cannabinoid-mediated antitumor effects, according to a press release from CURE. This will of course allow for better understanding and efficiency in treating cancer, and the possibility to identify new drug candidates.
CURE recently announced its formal entrance into the pharmaceutical cannabis sector, which is estimated to reach over $23 billion in the U.S. by 2020, according to ArcView. CURE’s goal is to bring new cannabinoid molecules to the market through the FDA regulatory process, while utilizing the company’s proprietary delivery technologies to increase efficacy, as well as to fill unmet needs in the pharmaceutical markets. As we know, FDA regulations require the medicine (especially if it is cannabis-based) to be able to be reproduced in a laboratory, and this kind of research will guarantee the evidence to be accessible, and the reproduction of the medicine to be stable and effective.
It is equally important to recognize that children deserve the chance to use natural and powerful medicine to let them live their lives cancer-free. CannaKids is dedicated to that goal, and Tracy Ryan, CEO of CannaKids has worked hard to get this partnership in order to further the research and acceptance of the cannabinoid medicines for children. “We are in a brave new world of plant-based cannabinoid medicines, and it is an honor to be working alongside such brilliant minds,” she said.
Ryan had initially reached out the Technion when her daughter was battling a rare brain tumor, and made good connections with the team at Technion. “I was elated to find groundbreaking research already taking place in a federally legal environment,” Ryan said. Technion is known for innovation in medicine, as a leading science and technology university with three Nobel Prize winners.
This new research will hopefully determine which cannabis strains might be used to tackle different cancer cells and have thorough evidence to support these claims and therapies. We already know cannabis can kill cancer cells, but it doesn’t always work for everyone—this collaboration wants to figure out how to make it full-proof for all subtypes, and what specific cannabinoid compounds are responsible for the ability to kill these cells.
